Meningococcal Vaccines market research report

Meningococcal Vaccines Market size is anticipated to register a healthy CAGR of 7.29% during the review period to reach USD 5.91 billion by the end of 2030. The key factors that drive the worldwide meningococcal antibodies market are the Rising mindfulness and flood in movement immunizations and the expansion in Research and development for antibody innovation. Expanding Consideration in Public Vaccination Projects is supposed to help the development of the meningococcal antibodies market. In any case, the rigid administrative rules and item reviews are expected to hamper market development.

The rising mindfulness about meningococcal antibodies and expanding antimicrobial of a few Neisseria meningitides clonal buildings is prompting a flood in vaccination programs across the globe. For example, a few Neisseria meningitides clonal buildings, especially CC4821 and CC11, keep on showing protection from anti-microbials. Furthermore, expanding episodes of meningococcal infections, likewise, drive the market. Besides, a rising number of voyagers and the incorporation of meningococcal immunization as an obligatory prerequisite for a couple of nations are likewise driving the market.

Market Segmentation

The market segmentation of meningococcal immunizations market is as follows

By Vaccine Type

Conjugate
Subcapsular
Polysaccharide

By Serotype

MenACWY
MenB/BC
MenC
MenAC
MenA

By End-user

Hospitals
Research & Academic Institutes
Others

Regional Analysis

North America ruled the worldwide meningococcal immunizations market in 2021. This is because of the presence of central members, a deeply grounded medical services foundation, ideal government drives for immunization improvement and conveyance, and an expansion in the quantity of Research and development associations. Moreover, adolescents, teens, and youthful grown-ups represent 21% of all meningococcal sickness cases in the US and are probably going to emphatically affect the meningococcal immunization market.

The meningococcal antibody market in Europe is being driven by non-benefit associations that give funding to explore projects, medical services proficient preparation, patient data and backing, and request driven by a critical expansion in routine vaccination.

As indicated by the European Place for Illness Counteraction and Control, obtrusive meningococcal sickness (IMD) is the main source of meningitis and septicemia, with an expected 200,000 cases happening every year. The sickness frequently advances quickly with a 8-15% case-casualty proportion. Certain European nations that are planning for a meningococcal immunization program are supporting the meningococcal immunization market.

The Asia-Pacific locale is supposed to show the most elevated CAGR from 2021 to 2030. This is because of the expanded transmission of meningococcal microbes which has brought about a critical expansion in the quantity of clinical projects for the viable improvement of meningococcal immunizations because of capricious events across various age gatherings and nations in the district. This has reinforced the Asia-Pacific meningococcal immunizations market.

Major Players

The prominent players operating in the global meningococcal vaccines market include Pfizer Inc (US), Novartis AG (Switzerland), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Sanofi S.A.(France), and Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Ltd (China), Bio-Manguinhos (Brazil).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: MRFR/HC/7150-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING AWARENESS AND SURGE IN TRAVEL VACCINE
- 4.2.2 INCREASE IN R&D FOR VACCINE TECHNOLOGY
4.3 RESTRAINTS
- 4.3.1 STRINGENT REGULATORY GUIDELINES AND PRODUCT RECALLS
4.4 OPPORTUNITIES
- 4.4.1 INCREASING INCLUSION IN NATIONAL IMMUNIZATION PROGRAMS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION & SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 BARGAINING POWER OF BUYERS
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL MENINGOCOCCAL VACCINES MARKET
- 5.3.1 OVERVIEW
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON PRODUCTION OF MENINGOCOCCAL VACCINE
- 5.3.4 IMPACT ON KEY PLAYERS

6 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE

6.1 OVERVIEW
6.2 CONJUGATE
6.3 SUBCAPSULAR
6.4 POLYSACCHARIDE

7 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE

7.1 OVERVIEW
7.2 MENACWY
7.3 MENB/BC
7.4 MENC
7.5 MENAC
7.6 MENA

8 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS
8.3 RESEARCH & ACADEMIC INSTITUTES
8.4 OTHERS

9 GLOBAL MENINGOCOCCAL VACCINES MARKET, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 UK
- 9.3.4 ITALY
- 9.3.5 SPAIN
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 JAPAN
- 9.4.2 CHINA
- 9.4.3 INDIA
- 9.4.4 AUSTRALIA
- 9.4.5 SOUTH KOREA
- 9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 MIDDLE EAST
- 9.5.2 AFRICA
- 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MENINGOCOCCAL VACCINES MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
- 10.6.2 PARTERSHIP/AGREEMENT
10.7 FINANCIAL MATRIX
- 10.7.1 SALES (USD MILLION), 2021
- 10.7.2 R&D EXPENDITURE (USD MILLION), 2021

11 COMPANY PROFILES

11.1 PFIZER INC.
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS/SERVICES OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 NOVARTIS AG
- 11.2.1 COMPANY OVERVIEWS
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS/SERVICES OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 SANOFI S.A.
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS/SERVICES OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 SERUM INSTITUTE OF INDIA PVT. LTD.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS/SERVICES OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 GLAXOSMITHKLINE PLC.
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS/SERVICES OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 MERCK & CO., INC.
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 KEY STRATEGIES
11.7 INCEPTA PHARMACEUTICALS LTD.
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS/SERVICES OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
11.8 BIO-MED
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 KEY STRATEGIES
11.9 WALVAX BIOTECHNOLOGY CO., LTD.
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS/SERVICES OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 BIO-MANGUINHOS
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS/SERVICES OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES
12.2 RELATED REPORTS